Health
Cancer Prevention
Female CEOs

Iovance Biotherapeutics

$15.62
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.58 (3.86%) Today
+$0.01 (0.06%) After Hours

Why Robinhood?

You can buy or sell IOVA and other stocks, options, ETFs, and crypto commission-free!

About

Iovance Biotherapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. Read More The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Employees
88
Headquarters
San Carlos, California
Founded
2007
Market Cap
1.85B
Price-Earnings Ratio
β€”
Dividend Yield
0.00
Average Volume
1.32M
High Today
$16.52
Low Today
$15.15
Open Price
$15.30
Volume
1.83M
52 Week High
$18.25
52 Week Low
$7.26

Collections

Health
Cancer Prevention
Female CEOs
Biotechnology
Medical
Therapy
Technology
2013 IPO

News

Seeking AlphaMay 18

Iovance Biotherapeutics: Updating The Investment Thesis

We revisit this promising developmental firm and its evolving investment case in the paragraphs below. We highlight recent trial data and what analysts are saying on the company. "Long books, when read, are usually overpraised, because the reader wishes to convince others and himself that he has not wasted his time.” ― E.M. Forster, Aspects of the Novel Iovance Biotherapeutics (IOVA) is one of several small biotech holdings making big moves this week for the Busted IPO Forum model portfolio. The company ...

481
BenzingaMay 16

Iovance Issues Cancer Trial Updates Ahead Of ASCO Meeting, Sending Stock Skyward

Shares of small-cap biotech Iovance Biotherapeutics Inc (NASDAQ: IOVA) were making a strong upward move Thursday on more than 10 times their average volume.

822
The Motley FoolMay 8

Iovance Biotherapeutics, Inc. (IOVA) Q1 2019 Earnings Call Transcript

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2019 Earnings Call , 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon, and welcome to the Iovance Biotherapeutics first-quarter 2019 financial results conference call. [Operator instructions] Please be advised that the call is being recorded at the company's request. Now I would like to turn the conference over to Tim Morris, chief financial officer at Iovance. Sir, please go ahea...

1,392

Earnings

-$0.36
-$0.33
-$0.30
-$0.27
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.29 per share
Actual
-$0.30 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.